Dextromethorphan (DXM) works by acting on several receptor systems in the brain, not just one. At standard cough-suppressing doses of 10 to 20 mg, it primarily blocks a type of brain receptor involved in signaling between nerve cells, which dampens the cough reflex. But DXM is unusually versatile for such a common over-the-counter drug. It also affects serotonin levels, activates a receptor involved in nerve cell protection, and at high doses produces dissociative effects similar to ketamine.
How DXM Suppresses Coughs
DXM suppresses coughs by acting on the brain rather than the throat or lungs. It’s classified as a centrally acting antitussive, meaning it reduces the urge to cough by quieting the neural circuits in the brainstem that coordinate the cough reflex. The key mechanism is its ability to block NMDA receptors, which are docking sites for glutamate, the brain’s main excitatory chemical messenger. By interfering with glutamate signaling in these circuits, DXM raises the threshold for triggering a cough.
At the recommended adult dose of 10 to 20 mg every four hours (up to 120 mg per day), this effect is mild and targeted enough that most people feel little else. The drug kicks in within 15 to 30 minutes of swallowing it and reaches peak blood levels in about two to three hours.
The Receptors DXM Targets
What makes DXM pharmacologically interesting is that it doesn’t just do one thing. It hits at least three distinct targets in the brain, each contributing different effects depending on the dose.
- NMDA receptors: DXM is an uncompetitive antagonist here, meaning it blocks the receptor only when it’s already been activated by glutamate. This is the same basic mechanism that makes ketamine work, though DXM binds with lower affinity. By reducing glutamate-driven excitation, DXM can suppress cough, reduce certain types of pain, and at higher doses produce dissociative mental states.
- Sigma-1 receptors: DXM activates these receptors, which sit inside cells and help regulate how nerve cells respond to stress. Sigma-1 activation is thought to have neuroprotective and mood-modulating effects. DXM binds to sigma-1 receptors with relatively high affinity, and this interaction is a major reason researchers have been interested in the drug for depression and neurological conditions.
- Serotonin and norepinephrine transporters: DXM inhibits the proteins that vacuum serotonin and norepinephrine back into nerve cells after they’ve been released. The result is more of these mood-related chemical messengers lingering in the gaps between neurons. This is essentially what many antidepressants do, though DXM was never designed for that purpose.
What Happens After You Swallow It
Once absorbed, DXM is rapidly processed by the liver. The primary enzyme responsible is CYP2D6, which converts DXM into a metabolite called dextrorphan. This is important because dextrorphan is pharmacologically active too. It’s actually a stronger NMDA receptor blocker than DXM itself, so much of the drug’s effect comes from this breakdown product rather than the original compound.
DXM has a half-life of roughly 1.4 to 3.9 hours, meaning half the original drug is cleared from your blood in that window. Dextrorphan sticks around a bit longer, with a half-life of 3.4 to 5.6 hours. A secondary metabolic pathway runs through a different liver enzyme, CYP3A4, producing another intermediate that’s eventually converted and excreted in urine.
Here’s where genetics come in. About 5 to 10 percent of people of European descent are “poor metabolizers,” meaning their CYP2D6 enzyme works very slowly or not at all. In these individuals, DXM stays in the bloodstream much longer and at higher concentrations, which can amplify both therapeutic and unwanted effects from a standard dose. This same enzyme variation is why DXM has long been used as a test drug to figure out how well a person’s CYP2D6 system works.
Why DXM Is Now Used for Depression
The combination of NMDA blocking, sigma-1 activation, and serotonin-norepinephrine reuptake inhibition gave DXM an unusual pharmacological profile that caught the attention of depression researchers. In 2022, the FDA approved a combination of DXM with bupropion for treating major depressive disorder in adults.
Bupropion serves a dual role in this pairing. It’s an antidepressant on its own, boosting dopamine and norepinephrine activity. But it also strongly inhibits CYP2D6, the liver enzyme that breaks down DXM. By slowing DXM’s metabolism, bupropion keeps DXM levels in the blood elevated and more stable, essentially turning everyone into a “slow metabolizer” on purpose. This allows DXM’s brain effects to persist long enough to be therapeutically useful for mood rather than just cough suppression.
What Happens at High Doses
At recreational doses, which range from 250 to 1,500 mg (far beyond the 120 mg daily maximum), DXM’s effects on the brain shift dramatically. People who misuse the drug describe four distinct levels of intensity, often called “plateaus,” that correspond to increasing doses adjusted for body weight.
At the lowest recreational dose, the experience resembles mild intoxication. The second level brings effects comparable to heavy alcohol use, with slurred speech, impaired short-term memory, and occasional mild hallucinations. The third level involves an altered state of consciousness with impaired senses, particularly vision. At the highest doses, users describe complete dissociation from their body, losing contact with their senses in a way comparable to the effects of ketamine or PCP.
These escalating effects map onto DXM’s pharmacology. At therapeutic doses, the NMDA blockade is subtle. As doses climb, NMDA receptors become increasingly blocked, glutamate signaling drops more dramatically, and the brain enters a dissociative state. The massive serotonin and sigma-1 activity at these doses adds hallucinogenic and euphoric qualities. Acute high doses can cause blurred vision, fever, rapid heart rate, elevated blood pressure, shallow breathing, and in severe cases, toxic psychosis or coma.
The Serotonin Syndrome Risk
Because DXM increases serotonin levels, combining it with other drugs that do the same thing can push serotonin into a dangerous range. This toxic state, called serotonin syndrome, causes a cluster of symptoms including agitation, confusion, rapid heart rate, high blood pressure, muscle twitching, and in severe cases, seizures or loss of consciousness.
The most common trigger is taking DXM while on an SSRI antidepressant like citalopram, sertraline, or fluoxetine. The interaction works through two pathways at once: the SSRI and DXM both independently raise serotonin levels, creating an additive effect. On top of that, many SSRIs inhibit CYP2D6, the enzyme that clears DXM from the body. So the person ends up with higher DXM levels lasting longer, amplifying the serotonin surge further. This combination is common enough that drug safety agencies have issued specific warnings about using DXM-containing cough medicines while taking SSRIs.
MAO inhibitors pose an even greater risk and should never be combined with DXM. The interaction can produce life-threatening serotonin toxicity even at normal cough-suppressing doses.